RANCHO CORDOVA, Calif., Aug. 1, 2011 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that Mahendra Rao, M.D., Ph.D. has resigned from the board, effective July 29, 2011.
"Dr. Rao has been appointed to a position with the National Institute of Health ("NIH"), which requires him to resign as a director of the Company, pursuant to NIH and federal government rules and regulations related to conflicts of interests. We are delighted for Mahendra as he takes on this exciting new responsibility, but we will miss his overall scientific and management contributions," said J. Melville Engle, Chairman and Chief Executive Officer of ThermoGenesis.
Concurrently, the Company announced Robin Stracey has joined the board to replace Dr. Rao. Stracey has more than 30 years of management experience in the biotech, life sciences and medical device sectors. He is currently Chairman, President and Chief Executive Officer of Cantimer Incorporated, a company developing devices to measure and monitor changes in human hydration.
He previously served as President and Chief Executive Officer of Applied Imaging Corporation, a publicly traded specialty medical device company in the fields of clinical cytogenetics, digital pathology and cancer research, which is now part of Danaher Corporation.Prior to Applied Imaging, Stracey was associated with Thermo Fisher Scientific, where he was Vice President and General Manager of a Chromatography and Mass Spectrometry business unit. Before that, he was Corporate Vice President and General Manager at Dade Behring Inc., which served the clinical laboratory market and is now owned by Siemens. He also held senior international, marketing and strategic development positions at E. I. DuPont de Nemours. He holds an Honors degree in Life Sciences from the University of Nottingham in the United Kingdom. "Robin's appointment is key for us as we continue our Company momentum. He brings a wealth of experience in both the life science tools and diagnostics sectors and his track record of achievement will be of great value to the management team as we continue to implement our growth strategy," Engle said.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV